BRAF Inhibitors Induce Feedback Activation of RAS Pathway in Thyroid Cancer Cells
<i>BRAF<sup>V600E</sup></i> is the most frequent oncogenic mutation identified in papillary thyroid cancer (PTC). In PTC patients who do not respond to standard treatment, BRAF inhibitors are currently tested as alternative strategies. However, as observed for other targeted...
Main Authors: | Elisa Bonaldi, Chiara Gargiuli, Loris De Cecco, Arianna Micali, Maria Grazia Rizzetti, Angela Greco, Maria Grazia Borrello, Emanuela Minna |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-05-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/22/11/5744 |
Similar Items
-
Characterization and Clinical Utility of <i>BRAF</i><sup>V600</sup> Mutation Detection Using Cell-Free DNA in Patients with Advanced Melanoma
by: Piotr Rutkowski, et al.
Published: (2021-07-01) -
<i>Snail-1</i> Overexpression Correlates with Metastatic Phenotype in BRAF<sup>V600E</sup> Positive Papillary Thyroid Carcinoma
by: Katarzyna Wieczorek-Szukala, et al.
Published: (2020-08-01) -
Risk factors for cervical lymph node metastasis in papillary thyroid microcarcinoma: a study of 1,587 patients
by: Xiangqian Zheng, et al.
Published: (2019-03-01) -
<sup>V600E</sup>BRAF Inhibition Induces Cytoprotective Autophagy through AMPK in Thyroid Cancer Cells
by: Eva Jiménez-Mora, et al.
Published: (2021-06-01) -
Prospective Analysis of <i>TERT</i> Promoter Mutations in Papillary Thyroid Carcinoma at a Single Institution
by: Yun-Suk Choi, et al.
Published: (2021-05-01)